Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXingyu CaoYZYang ZhangDLDeyan Liu

Discussion

Loading...

Member takes

Overview

Analysis shows worsened survival outcomes in hematologic malignancies post-allo-HSCT, indicating TP53 mutations correlate with higher relapse rates.

Key Points

  • TP53 mutations in hematologic malignancies are linked to lower survival rates and higher relapse occurrences.
  • Cumulative incidence rates suggest significant prognostic differentiation based on germline and somatic TP53 status.
  • Engraftment rates are high across patient groups, with a median time of about two weeks post-transplant.
  • Identifying TP53 mutation types may guide treatment decisions and improve transplant outcomes for patients.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2e2https://doi.org/10.1182/blood-2025-7786
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  2. 2Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  3. 3Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  4. 4Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  5. 5Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT2025 · 1 citations